Vivanza Biosciences Ltd (VIVANZA) — shareholding pattern, promoter holding, financials and share price
About Vivanza Biosciences Ltd (VIVANZA)
Vivanza Biosciences Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as VIVANZA and on the BSE under scrip code 530057. Its ISIN is INE984E01035.
Incorporated in 2016, Vivanza Biosciences Ltd is in the business of providing medicines and healthcare solutions [1]
Vivanza Biosciences Limited is a pharmaceutical company focusing on both novel and generic pharmaceutical products.
Established in 1982, it has faced challenges but rebranded to expand its market reach globally.
Listed peers in Pharmaceuticals: Unjha Formulations Ltd, Colinz Laboratories Ltd, Ganga Pharmaceuticals Ltd, Decipher Labs Ltd, Brawn Biotech Ltd, Fabino Enterprises Ltd.
Valuation & Returns
10 Jul 2026At ₹1.79 a share on 10 Jul 2026, Vivanza Biosciences Ltd (VIVANZA) was valued at a price-to-earnings ratio of 17.9x against an industry P/E of 36.41x and a price-to-book of 1.81x on a book value of ₹0.99 per share as of Mar 2025. Solomo computes return on equity of 10.09% and return on capital employed of 6.66% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 17.9x
- Industry P/E
- 36.41x
- P/B
- 1.81x
- EPS (TTM)
- ₹0.1
- Book value / share
- ₹0.99
- ROE
- 10.09%
- ROCE
- 6.66%
- ROA
- 2.43%
- Debt / equity
- 2.18x
- Dividend yield
- 0%
- EBITDA margin
- 0.73%
- 52-week range
- ₹1.52 – ₹2.72
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Vivanza Biosciences Ltd (VIVANZA) reported revenue of ₹116 crore and earnings per share of ₹0.1. That compares with revenue of ₹7 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹6.36 crore and net profit ₹-0.45 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 10 | 18 | 28 | 7 | 116 |
| Net profit (₹ cr) | 0 | 1 | 1 | -1 | 0 |
| EPS (₹) | 0.08 | 0.15 | 0.14 | -0.17 | 0.1 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | - | -20.78% | -31.48% | -73.35% |
| Profit growth | - | - | - | -221.82% |
| Stock price CAGR | -9% | -31% | -50% | -14% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 20.02% of Vivanza Biosciences Ltd (VIVANZA) (unchanged from the previous quarter) and domestic institutional investors (DII) hold 0%. Market capitalisation was ₹7 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Mar 2026: ASHOKA METCAST LIMITED 3.85%, HUF 2.07%, PRASHANT TYAGI 1.51%, RAVINDER SINGH 1.5%, MANU NARANG 1.31%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 20.02% | - | - | 0% | 79.98% |
| Dec 2025 | 20.02% | - | - | 0% | 79.98% |
| Sep 2025 | 20.02% | - | - | 0% | 79.98% |
| Jun 2025 | 20.02% | - | - | 0% | 79.98% |
| Mar 2025 | 20.02% | - | - | 0% | 79.98% |
| Dec 2024 | 20.02% | - | - | 0% | 79.98% |
| Sep 2024 | 39.86% | - | - | 0% | 60.14% |
| Jun 2024 | 40.05% | - | - | 0% | 59.95% |